

Farhad Vesuna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2565264/publications.pdf>

Version: 2024-02-01

38
papers

2,979
citations

331670

21
h-index

330143

37
g-index

39
all docs

39
docs citations

39
times ranked

4929
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. <i>Oncogene</i> , 2009, 28, 2940-2947.	5.9	640
2	Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. <i>Biochemical and Biophysical Research Communications</i> , 2008, 367, 235-241.	2.1	318
3	Twist Overexpression Induces <i>in vivo</i> Angiogenesis and Correlates with Chromosomal Instability in Breast Cancer. <i>Cancer Research</i> , 2005, 65, 10801-10809.	0.9	257
4	Twist Modulates Breast Cancer Stem Cells by Transcriptional Regulation of CD24 Expression. <i>Neoplasia</i> , 2009, 11, 1318-1328.	5.3	195
5	Targeting DDX3 with a small molecule inhibitor for lung cancer therapy. <i>EMBO Molecular Medicine</i> , 2015, 7, 648-669.	6.9	189
6	Oncogenic role of DDX3 in breast cancer biogenesis. <i>Oncogene</i> , 2008, 27, 3912-3922.	5.9	184
7	Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor- α . <i>Oncogene</i> , 2012, 31, 3223-3234.	5.9	135
8	Hypoxia Regulates Choline Kinase Expression through Hypoxia-Inducible Factor-1 α Signaling in a Human Prostate Cancer Model. <i>Cancer Research</i> , 2008, 68, 172-180.	0.9	124
9	The Transcription Factor Encyclopedia. <i>Genome Biology</i> , 2012, 13, R24.	9.6	103
10	The Twist Box Domain Is Required for Twist1-induced Prostate Cancer Metastasis. <i>Molecular Cancer Research</i> , 2013, 11, 1387-1400.	3.4	79
11	Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer. <i>Oncotarget</i> , 2015, 6, 28312-28326.	1.8	79
12	Peptides Derived from Type IV Collagen, CXC Chemokines, and Thrombospondin-1 Domain-Containing Proteins Inhibit Neovascularization and Suppress Tumor Growth in MDA-MB-231 Breast Cancer Xenografts. <i>Neoplasia</i> , 2009, 11, 1285-IN2.	5.3	58
13	Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment. <i>Oncogene</i> , 2018, 37, 63-74.	5.9	58
14	RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3. <i>Cancer Research</i> , 2016, 76, 6340-6350.	0.9	56
15	Novel, Broad Spectrum Anticancer Agents Containing the Tricyclic 5:7:5-Fused Diimidazodiazepine Ring System. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 252-256.	2.8	53
16	Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer. <i>NMR in Biomedicine</i> , 2012, 25, 1033-1042.	2.8	45
17	NZ51, a ring-expanded nucleoside analog, inhibits motility and viability of breast cancer cells by targeting the RNA helicase DDX3. <i>Oncotarget</i> , 2015, 6, 29901-29913.	1.8	45
18	Organ-specific isogenic metastatic breast cancer cell lines exhibit distinct Raman spectral signatures and metabolomes. <i>Oncotarget</i> , 2017, 8, 20266-20287.	1.8	41

#	ARTICLE	IF	CITATIONS
19	Expression of DDX3 Is Directly Modulated by Hypoxia Inducible Factor-1 Alpha in Breast Epithelial Cells. PLoS ONE, 2011, 6, e17563.	2.5	37
20	Targeting DDX3 in Medulloblastoma Using the Small Molecule Inhibitor RK-33. Translational Oncology, 2019, 12, 96-105.	3.7	31
21	HOXA5 Regulates hMLH1 Expression in Breast Cancer Cells. Neoplasia, 2006, 8, 250-258.	5.3	26
22	Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer. Medical Oncology, 2017, 34, 33.	2.5	23
23	Nuclear DDX3 expression predicts poor outcome in colorectal and breast cancer. OncoTargets and Therapy, 2017, Volume 10, 3501-3513.	2.0	22
24	Global Effects of DDX3 Inhibition on Cell Cycle Regulation Identified by a Combined Phosphoproteomics and Single Cell Tracking Approach. Translational Oncology, 2018, 11, 755-763.	3.7	21
25	Enhanced green fluorescent protein as an alternative control reporter to Renilla luciferase. Analytical Biochemistry, 2005, 342, 345-347.	2.4	20
26	miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers. Oncotarget, 2015, 6, 32115-32137.	1.8	20
27	Targeting host DEAD-box RNA helicase DDX3X for treating viral infections. Antiviral Research, 2021, 185, 104994.	4.1	19
28	Twist overexpression promotes chromosomal instability in the breast cancer cell line MCF-7. Cancer Genetics and Cytogenetics, 2006, 167, 189-191.	1.0	17
29	Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models. Cancer Biology and Therapy, 2007, 6, 891-897.	3.4	17
30	Genomic pathways modulated by Twist in breast cancer. BMC Cancer, 2017, 17, 52.	2.6	15
31	Twist activates miR-22 to suppress estrogen receptor alpha in breast cancer. Molecular and Cellular Biochemistry, 2021, 476, 2295-2306.	3.1	13
32	Targeting RNA helicase DDX3 in stem cell maintenance and teratoma formation. Genes and Cancer, 2019, 10, 11-20.	1.9	11
33	Role of DDX3 in the pathogenesis of inflammatory bowel disease. Oncotarget, 2017, 8, 115280-115289.	1.8	9
34	Hypoxia-induced human endonuclease G expression suppresses tumor growth in a xenograft model. Cancer Gene Therapy, 2008, 15, 645-654.	4.6	6
35	Histamine: A potential therapeutic agent for breast cancer treatment?. Cancer Biology and Therapy, 2006, 5, 1472-1473.	3.4	5
36	Divergent organ-specific isogenic metastatic cell lines identified using multi-omics exhibit differential drug sensitivity. PLoS ONE, 2020, 15, e0242384.	2.5	3

#	ARTICLE	IF	CITATIONS
37	GDPD5 inhibition alters the choline phospholipid metabolite profile of breast cancer cells toward a less malignant metabolic profile. <i>Biomedical Spectroscopy and Imaging</i> , 2012, 1, 3-15.	1.2	2
38	Detection and Evaluation of Non-Recombinants in cDNA Libraries by Multiple Cloning Region PCR. <i>BioTechniques</i> , 2002, 32, 88-92.	1.8	0